latest news releases from the newsroom
Amersham plc appoints Peter Loescher as Chief Operating Officer
BUCKINGHAMSHIRE, U.K., Nov. 14, 2003 (PRIMEZONE) -- Amersham plc (LSE:AHM) (NYSE:AHM) (OSE:AHM) today announces the appointment of Peter Loescher to the role of Chief Operating Officer, effective 1 January 2004. Mr. Loescher, 46, joined the company in December 2002 as President of Amersham Health and an Executive member of the Amersham plc Board.
Delhaize Group sells interest in Singapore retailer Shop N Save
BRUSSELS, Belgium, Nov. 14, 2003 (PRIMEZONE) -- Delhaize Group (Euronext Brussels:DELB) (NYSE:DEG), the Belgian international food retailer, announced today it has reached a binding share purchase agreement to sell its 49% shareholding in the Singapore food retailer, Shop N Save, to Singapore retailer Cold Storage Singapore (1983) Pte. Ltd., a wholly owned subsidiary of the Hong Kong-based Dairy Farm group for an amount of SGD 44.1 million (EUR 21.9 million).
Skanska secures US highway contract valued at SEK 715 M
STOCKHOLM, Sweden, Nov. 14, 2003 (PRIMEZONE) -- Skanska has received a contract to construct a new highway in North Carolina, in the US. The contract is valued at SEK 715 M (USD 94 M) and the customer is the North Carolina Department of Transportation. The contract will be included in order bookings for the fourth quarter of 2003.
Trintech Group Plc
Trintech Group Announces Acquisition of DataFlow Services
DUBLIN, Ireland and DALLAS, Nov. 14, 2003 (PRIMEZONE) -- Trintech Group Plc (Nasdaq:TTPA (Prime Standard:TTP), a leading provider of transaction management and payment infrastructure solutions, today announced the acquisition of CW & Associates, Inc, trading as DataFlow Services, a private company, for a total consideration of approximately $5 million.
Crucell Presents Encouraging Results of its Malaria Vaccine Program
LEIDEN, The Netherlands and LAS VEGAS, Nov. 14, 2003 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Nasdaq:CRXL) (Euronext:CRXL) presented encouraging study results on the efficacy of an experimental malaria vaccine at this week's Viral Vectors & Vaccines conference held in Las Vegas. The study is part of a close collaboration between Crucell and the Department of Medical and Molecular Parasitology at New York University (NYU) to provide proof of principle that a vaccine based on Crucell's AdVac(TM) technology1 is able to confer protection against malaria.